Login to Your Account

Affitech's AT001 Enters Clinic, as Delisting Looms

By Cormac Sheridan
Staff Writer

Tuesday, August 21, 2012

Clinical testing of Affitech A/S' lead antibody, AT001/r84, began this week, just as the company enters its final weeks as a publicly quoted entity and prepares to become a private entity, wholly owned by Russian investors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription